

### primary studies - published RCT

# Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis.

Code: PM21518837 Year: 2011 Date: 2011

Author: Keel RA

## Study design (if review, criteria of inclusion for studies)

RCT, crossover design with a 9-day washout.

## **Participants**

8 adults with CF

#### Interventions

patients were randomized to receive intravenous (i.v.) and oral linezolid at 600 mg twice daily for 9 doses in a crossover design with a 9-day washout.

## **Outcome measures**

Plasma samples were collected after the first and ninth doses of each phase. Population pharmacokinetic analyses were performed by nonlinear mixed-effects modeling using a previously described 2-compartment model with time-dependent clearance inhibition. Monte Carlo simulation was performed to assess the activities of the linezolid dosing regimens against 42 contemporary MRSA isolates recovered from CF patients.

#### Main results

The following pharmacokinetic parameter estimates were observed for the population: absorption rate constant, 1.91 h(-1); clearance, 9.54 liters/h; volume of central compartment, 26.8 liters; volume of peripheral compartment, 17.3 liters; and intercompartmental clearance, 104 liters/h. Linezolid demonstrated nonlinear clearance after 9 doses, which was reduced by a mean of 38.9% (range, 28.8 to 59.9%). Mean bioavailability was 85% (range, 47 to 131%). At steady state, 600 mg given twice daily produced 93.0% and 87.2% probabilities of obtaining the target pharmacodynamic exposure against the MRSA isolates for the i.v. and oral formulations, respectively. Thrice-daily dosing increased the probabilities to 97.0% and 95.6%, respectively. Linezolid pharmacokinetics in these adults with CF were well described by a 2-compartment model with time-dependent clearance inhibition. Standard i.v. and oral dosing regimens should be sufficient to reliably attain pharmacodynamic targets against most MRSA isolates; however, more frequent dosing may be required for isolates with MICs of  $\hat{a}_{W} \neq 2 \hat{1}_X g/ml$ .

http://dx.doi.org/10.1128/AAC.01797-10

## See also

Antimicrobial agents and chemotherapy

#### Keywords

Bacterial Infections; Infection; pharmacological\_intervention; Respiratory Tract Diseases; Respiratory Tract Infections; Anti-Bacterial Agents; Adult; Linezolid; Staphylococcus aureus; Intravenous; Oral; other anti-bacterial agents;